Lataa...
Emerging options for the treatment of melanoma – focus on ipilimumab
Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-T-lymphocyte-antigen-4 monoclonal antibody. It has been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency for use in advanced melanoma following clear evidence of survival benefit in randomized...
Tallennettuna:
| Julkaisussa: | Immunotargets Ther |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4918235/ https://ncbi.nlm.nih.gov/pubmed/27482517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S43522 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|